Literature DB >> 23100991

Pulmonary hypertension in patients with hematological disorders following splenectomy.

V Meera1, Farah Jijina, Kanjaksha Ghosh.   

Abstract

Prevalence of pulmonary arterial hypertension (PAH) was studied by Echocardiography and Doppler in 43 splenectomised patients with various disorders 1-20 years after splenectomy. PAH was detected only in thalassemia major, intermedia, hereditary sphereocytosis and myelofibrosis groups comprising a total of 21 patients. Six patients out of 21 was found to have PAH with mean pulmonary arterial pressure of 46.28 ± 28.17 mmHg. Twenty one controls having similar duration and type of disease also were assessed for PAH in this case control study 3/21 had PAH in this control group. The difference in number of patients showing pulmonary hypertension between case and control was not statistically significant (chi-square test p = 0.29-though the difference in pulmonary arterial pressure between case and control were significantly different (t-test p<0.0029) with control group showing a mean pulmonary arterial pressure of 25 ± 19 mmHg.Platelet count in the splenectomised group was significantly higher (p = 0.0029) than the controls. Pulmonary thromboembolism was equally high in the PAH patients with and without splenectomy. Patients undergoing splenectomy due to trauma, immune thrombocytopenia, sideroblastic anemia, extra hepatic portal hypertension, autoimmune hemolytic anemia did not show PAH after splenectomy even years after the procedure PAH following splenectomy is common after certain disorders and control patients with these diseases have tendency to develop PAH even without splenectomy. Pulmonary thromboembolism may be an important pathophysiological mechanism leading to this condition. Patients having hemolytic anemia and myelofibrosis should have regular evaluation of pulmonary arterial pressure whether he/she has been splenectomised or not. This is particularly important as availability of phosphodiesterase inhibitors like sildenafil allows one to manage these cases.

Entities:  

Keywords:  Myelofibrosis; PAH; Pulmonary thromboembolism; Splenectomy; Thalassemia intermedia; Thalassemia major

Year:  2010        PMID: 23100991      PMCID: PMC3452946          DOI: 10.1007/s12288-010-0002-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  15 in total

1.  Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.

Authors:  Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2009-01-22       Impact factor: 21.405

Review 2.  The hypercoagulable state in thalassemia.

Authors:  Amiram Eldor; Eliezer A Rachmilewitz
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

3.  Angiogenesis in pulmonary hypertension with myelofibrosis.

Authors:  Eva Zetterberg; Uday Popat; Hans Hasselbalch; Josef Prchal; Jan Palmblad
Journal:  Haematologica       Date:  2008-05-06       Impact factor: 9.941

4.  Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS).

Authors:  Carlos J Bidot; Wenche Jy; Lawrence L Horstman; Eugene R Ahn; Miriam Yaniz; Yeon S Ahn
Journal:  Am J Hematol       Date:  2006-06       Impact factor: 10.047

5.  Splenectomy and chronic thromboembolic pulmonary hypertension.

Authors:  X Jaïs; V Ioos; C Jardim; O Sitbon; F Parent; A Hamid; E Fadel; P Dartevelle; G Simonneau; M Humbert
Journal:  Thorax       Date:  2005-08-05       Impact factor: 9.139

6.  Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia.

Authors:  Athanasios Aessopos; Dimitrios Farmakis; Spyros Deftereos; Maria Tsironi; Stergios Tassiopoulos; Ioannis Moyssakis; Markisia Karagiorga
Journal:  Chest       Date:  2005-05       Impact factor: 9.410

7.  Intravenous injection of sonicated blood induces pulmonary microthromboembolism in rabbits with ligation of the splenic artery.

Authors:  A Kisanuki; S Kietthubthew; Y Asada; K Marutsuka; Y Funahara; A Sumiyoshi
Journal:  Thromb Res       Date:  1997-01-15       Impact factor: 3.944

Review 8.  Pulmonary thromboembolism in thalassemic patients.

Authors:  D Sonakul; S Fucharoen
Journal:  Southeast Asian J Trop Med Public Health       Date:  1992       Impact factor: 0.267

9.  Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders.

Authors:  Vichai Atichartakarn; Khanchit Likittanasombat; Suporn Chuncharunee; Pakorn Chandanamattha; Surapon Worapongpaiboon; Pantep Angchaisuksiri; Katcharin Aryurachai
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

Review 10.  [Clinical use of phosphodiesterase-5 inhibitors in cardiopulmonary diseases: from experimental evidence to clinical application].

Authors:  Marco Guazzi; Marco Vicenzi; Michele Samaja
Journal:  G Ital Cardiol (Rome)       Date:  2009 Nov-Dec
View more
  2 in total

Review 1.  Splenectomy for immune thrombocytopenia: down but not out.

Authors:  Shruti Chaturvedi; Donald M Arnold; Keith R McCrae
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

Review 2.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.